Should You Buy ADMA Biologics Inc Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, ADMA Biologics Inc (ADMA) ranks in the top tier of our coverage universe with a Quality of Company score of 10.0/10. Trading at a market price of $8.71, this high-quality profile requires careful comparison against our 13 intrinsic value models.
The short answer: 4 of 13 CirclFi valuation models project upside for ADMA Biologics Inc (ADMA) at $8.71 — the model consensus leans bearish, with a Quality Score of 10.0/10 and Value-Trap risk of 6/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $15.33 (+76.0% upside)
- According to the CirclFi Quality of Company (QOC) framework, ADMA Biologics Inc's quality score of 10.0/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation.
- According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model targets a fair value of $15.33 (+76.0%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
- Industry tailwind: first-mover advantage in novel targets could provide meaningful support for ADMA Biologics Inc's revenue and margin trajectory in the Biotechnology space.
The Bear Case
Target: $1.26 (-85.5%)
- According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $1.26 (-85.5%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +161.5% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
- Industry headwind: competitive pipeline overlap represents a meaningful risk for ADMA Biologics Inc and its Biotechnology peers.
The Bottom Line
Caution dominates our read on ADMA Biologics Inc at $8.71. 8 of 13 models see limited upside or outright downside, with the composite fair value at $7.94 (-8.9%). Quality at 10.0/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.
These are quantitative model outputs, not investment recommendations. ADMA Biologics Inc's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy ADMA stock right now?
Based on CirclFi's multi-model analysis, 4 of 13 models see upside for ADMA at $8.71. The models are divided, which means the investment case depends heavily on your assumptions about ADMA Biologics Inc's future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in ADMA Biologics Inc?
Key risks include: wide model disagreement (1112% spread), signaling high uncertainty; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does ADMA compare to its competitors?
Among Biotechnology peers, ADMA holds a Quality Score of 10.0/10. Comparable companies include CPRX (QOC 10.0), EXEL (QOC 10.0), HALO (QOC 10.0). The relative ranking helps investors identify whether ADMA offers better fundamental quality than alternatives in the same sector.
Is ADMA a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ADMA's Quality Score of 10.0/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy ADMA at?
CirclFi does not provide target buy prices or price alerts. However, our 13 active models produce fair value estimates ranging from $1.26 to $15.33. At $8.71, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for ADMA.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad